Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.
Referral for initial ECT index course for Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression. Historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for TRD diagnostic.
Diagnoses of schizophrenia or schizoaffective disorders.
Subjects who are unable to tolerate the Dreem device for sleep recordings will be excluded from the study.
Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression
Cohort
Prospective
Electroencephalography (EEG)
Diagnostic testHigh-density EEG will be acquired during resting wakefulness before each ECT session.
Quantitative Measurements of Sleep Microstructure
Diagnostic testOvernight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
Slow wave activity (SWA) during non-rapid eye movement sleep (NREM) stage N2/N3
Total power of EEG slow waves per minute present during N2/N3 sleep
Graph-based neural connectivity measure of local efficiency of information transfer (Elocal) during wakefulness
Elocal will be calculated as the average inverse shortest path length among neighbors of a node within the network. Nodes will be constructed based on 5-minute recordings of eyes closed wakefulness theta band (4-8 Hz) EEG.
Graph-based neural connectivity measure of global information transfer (Eglobal) during ECT-induced seizure
Eglobal will be calculated as the average inverse shortest path length between node pairs in the networks. Nodes will be constructed based on ECT-induced seizure EEG data within the alpha band (8-13 Hz).
Click on the lead sponsor to view all of their trials.
Washington University School of Medicine
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
